Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Annual General Meeting – Corporate UpdateDecember 22, 2020
Private clinical company operating in San Francisco and Calgary
• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi
Company Profile and Highlights
PD-1
PD-L1
PARPi
CDK4/6i
ZEN-3694
ARi
BCL2i PI3Ki
CYP17ai
JAKi
MEKi
These specific oncology targets represent the hottest advancement areas in cancer fighting today!
The Cocktail Approach:
MultipleSynergistic Targets
Private clinical company operating in San Francisco and Calgary
• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi
• Registration enabling studies in process for 2021
Company Profile and Highlights
PD-1
PD-L1
PARPi
CDK4/6i
ZEN-3694
ARi
BCL2i PI3Ki
CYP17ai
JAKi
MEKi
These specific oncology targets represent the hottest advancement areas in cancer fighting today!
The Cocktail Approach:
MultipleSynergistic Targets
Private clinical company operating in San Francisco and Calgary
• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi
• Registration enabling studies in process for 2021• ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)
Company Profile and Highlights
PD-1
PD-L1
PARPi
CDK4/6i
ZEN-3694
ARi
BCL2i PI3Ki
CYP17ai
JAKi
MEKi
These specific oncology targets represent the hottest advancement areas in cancer fighting today!
The Cocktail Approach:
MultipleSynergistic Targets
Private clinical company operating in San Francisco and Calgary
• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi
• Registration enabling studies in process for 2021• ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)• ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone
Company Profile and Highlights
PD-1
PD-L1
PARPi
CDK4/6i
ZEN-3694
ARi
BCL2i PI3Ki
CYP17ai
JAKi
MEKi
These specific oncology targets represent the hottest advancement areas in cancer fighting today!
The Cocktail Approach:
MultipleSynergistic Targets
Private clinical company operating in San Francisco and Calgary
• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi
• Registration enabling studies in process for 2021• ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)• ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone
• National Cancer Institute clinical collaboration for developing multiple BETi combination therapies in molecularly defined cancers
Company Profile and Highlights
PD-1
PD-L1
PARPi
CDK4/6i
ZEN-3694
ARi
BCL2i PI3Ki
CYP17ai
JAKi
MEKi
These specific oncology targets represent the hottest advancement areas in cancer fighting today!
The Cocktail Approach:
MultipleSynergistic Targets
Private clinical company operating in San Francisco and Calgary
• Global lead in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs• + PARPi • + AR antagonists • + Immune checkpoint Mabs• + MEKi
• Registration enabling studies in process for 2021• ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)• ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone
• National Cancer Institute clinical collaboration for developing multiple BETi combination therapies in molecularly defined cancers
• Strong partnerships with multinational pharmaceutical companies
Company Profile and Highlights
PD-1
PD-L1
PARPi
CDK4/6i
ZEN-3694
ARi
BCL2i PI3Ki
CYP17ai
JAKi
MEKi
These specific oncology targets represent the hottest advancement areas in cancer fighting today!
The Cocktail Approach:
MultipleSynergistic Targets
ZEN-3694 BETi Programs Phase 1 Phase 2 Pivotal
AR independent mCRPC - Prostate (+ enzalutamide)
TNBC (+ talazoparib) - Breast
AR Independent CRPC - Prostate(+ Keytruda + enzalutamide)
Zenith’s Clinical Pipeline (no assigned rights except China)
Other Combinations(+ PARPi,+MEKi, CDK4/6i, chemo)
HR+ breast, CRC, Ovarian, CRPC, NmC
Pre-Clin
Newsoara (China)
Immune-oncology Combinations(+ PD-1 Mab + anti-CTLA4 Mab)
Ovarian, TNBC, Melanoma
Published Prostate Trial DataPrimary resistance to abiraterone data is advancing to Phase 2b/3 in China first
Clinical data and AI platform show that both ZEN-3694 and
enzalutamide required for durable
PSA response
0
5
10
15
20
25
30
35
40
45
-40 -20 0 20 40 60 80 100 120
PSA
ug/
L
Weeks on ZEN-3694
ZEN-3694 + enzalutamide Prior abiraterone
Three patients with significant and durable PSA response, after poor response to abiraterone
Pfizer & Zenith Combination Therapy Study: Triple Negative Breast Cancer (TNBC) Results
Slide material and content compiled by Pfizer Inc.
Study Design
Slide material and content compiled by Pfizer Inc.
12
Drug and Dosing Combinations
Slide material and content compiled by Pfizer Inc.
13
Trial Results
Slide material and content compiled by Pfizer Inc.
14
Trial Conclusions and Results
Slide material and content compiled by Pfizer Inc.
TNBC Program Highlights Significant Breakthrough in PARP Combo
15
ZEN-3694 + TalazoparibBiomarker selected (N=17)
ZEN-3694+Talazoparib Biomarker unselected (N=13)
All patients (N=30)
ORR % 41% 8% 27%
CBR (> 4 mo) % 59% 29% 45%
CBR (> 6 mo) % 56% 8% 43%
004-
017-
001
(C3)
004-
020-
018
(C3)
004-
012-
048
(C3)
004-
012-
036
(C3)
004-
014-
045
(C3)
004-
012-
007
(C3)
004-
021-
049
(C3)
004-
021-
015
(C3)
004-
016-
034
(C3)
004-
017-
010
(C3)
004-
020-
047
(C3)
004-
020-
038
(C3)
004-
017-
023
(C3)
004-
021-
025
(C3)
004-
011-
022
(C7)
004-
019-
033
(C3)
004-
014-
019
(C3)
004-
019-
035
(C6)
004-
011-
040
(C3)
004-
011-
037
(C5)
004-
019-
046
(C3)
004-
017-
002
(C5)
004-
019-
039
(C3)
004-
018-
014
(C11
)
004-
021-
042
(C3)
004-
021-
030
(C5)
004-
018-
008
(C7)
004-
018-
006
(C5)
004-
018-
020
(C3)
-100
-50
0
50
100
%C
han
ge
in
Ta
rget
Les
ion
s Biomarker selected
Biomarker unselected
PD= 20% increase
PR= 30% decrease
Slide material and content compiled by Pfizer Inc.
Legend:
PD: Progressive DiseasePR: Partial ResponseORR: Overall Response Rate (Complete Response + Partial Response)CBR: Clinical Benefit Rate (ORR + Stable Disease)
TNBC Program Highlights Significant Breakthrough in PARP Combo
16
ZEN-3694 + TalazoparibBiomarker selected (N=17)
ZEN-3694+Talazoparib Biomarker unselected (N=13)
All patients (N=30)
ORR % 41% 8% 27%
CBR (> 4 mo) % 59% 29% 45%
CBR (> 6 mo) % 56% 8% 43%
004-
017-
001
(C3)
004-
020-
018
(C3)
004-
012-
048
(C3)
004-
012-
036
(C3)
004-
014-
045
(C3)
004-
012-
007
(C3)
004-
021-
049
(C3)
004-
021-
015
(C3)
004-
016-
034
(C3)
004-
017-
010
(C3)
004-
020-
047
(C3)
004-
020-
038
(C3)
004-
017-
023
(C3)
004-
021-
025
(C3)
004-
011-
022
(C7)
004-
019-
033
(C3)
004-
014-
019
(C3)
004-
019-
035
(C6)
004-
011-
040
(C3)
004-
011-
037
(C5)
004-
019-
046
(C3)
004-
017-
002
(C5)
004-
019-
039
(C3)
004-
018-
014
(C11
)
004-
021-
042
(C3)
004-
021-
030
(C5)
004-
018-
008
(C7)
004-
018-
006
(C5)
004-
018-
020
(C3)
-100
-50
0
50
100
%C
han
ge
in
Ta
rget
Les
ion
s Biomarker selected
Biomarker unselected
PD= 20% increase
PR= 30% decrease
TRODELVY(Marketed by Gilead)
ORR = 35%
CBR (> 6 mo) =45%
Legend:
PD: Progressive DiseasePR: Partial ResponseORR: Overall Response Rate (Complete Response + Partial Response)CBR: Clinical Benefit Rate (ORR + Stable Disease)
UCSF-initiated clinical study using Keytruda, Enzalutamide and ZEN-3694 for mCRPC – study design published
2020 Milestones Leading to Major Collaborations
Spun out from Resverlogix Corp. 2013Zenith
Q1-2020
Q2-2020
Q3-2020
Q4-2020
Received US$5M milestone payment from Newsoara (China region partnership) upon successful completion of Ph2 mCRPC US study in combination with enzalutamidePh2 Collaboration with Pfizer
continues (TNBC) – moves towards efficacy stage
NCI CRADA announced. Clinical collaboration for multiple oncology clinical trials with different combination agents
First NCI CRADA study announced, NCI co-collaborating with Zenith and Bristol Myers Squibb (BMS) investigating ZEN-3694 with nivolumab and ipilimumab –in resistant ovarian cancer
Ph2 Collaboration with Pfizer proceeds to final efficacy stage of the Ph2 TNBC trial – advancing towards future registration
Regulatory advancement in China for ph2b/3 mCRPC study – paving way for worldwide development
Annual General Meeting – Questions & AnswersDecember 22, 2020